Search | Clinical Trials Finder

Conditions: Driving Behavior
Interventions: Xanax 1Mg Tablet, Norco 10Mg-325Mg Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Timothy L. Brown; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Acute Pain
Interventions: VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 9 more

Conditions: Low Back Pain
Interventions: Hydrocodone ER, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 87
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 71 more

Conditions: Pain
Interventions: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Analgesic Response
Interventions: morphine sulfate, hydrocodone, hydromorphone HCI, oxycodone, buprenorphine, oral tablet placebo, sublingual tablet placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colon Cancer, Colon Diverticulosis, Colonic Neoplasms, Colonic Diverticulitis, Pain, Postoperative, Ileus, Ileus Paralytic, Ileus; Mechanical, Constipation Drug Induced, Constipation, Rectum Cancer, Rectum Neoplasm
Interventions: Acetaminophen, Gabapentin, Orphenadrine, Lidocaine, Marcaine, Ketamine, Methadone, Tramadol, Ketorolac, Morphine Sulfate, Fentanyl, Dilaudid, Hydrocodone-Acetaminophen Tab 5-325 MG, HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET; Drug
Lead sponsor: University of Illinois College of Medicine at Peoria; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Pain, Hernia
Interventions: Ibuprofen, Opioid Medication, Placebo, Ibuprofen + Opioid medication; Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions: medrol dosepak, HYDROcodone Oral Tablet; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Pain
Interventions: Hydrocodone/Acetaminophen Extended Release, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Pasadena, California • Austin, Texas • Salt Lake City, Utah

Conditions: Rotator Cuff Tear Arthropathy
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Renal Impairment
Interventions: Hydrocodone Bitartrate extended-release tablet; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Pain, Postoperative
Interventions: Norco 5Mg-325Mg Tablet, Tylenol 325Mg Caplet, Ibuprofen 200 mg; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Pain
Interventions: Hydrocodone ER; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 54
States / cities: Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more

Conditions: Acute Pain
Interventions: SUZ, HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,075 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Acute Pain
Interventions: VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 7
States / cities: Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 4 more

Conditions: Pain
Interventions: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Postoperative Pain
Interventions: Plain bupivacaine, Liposomal bupivacaine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Femoracetabular Impingement, Hip Arthroscopy
Interventions: Ketorolac, Control (Standard treatment), Omeprazole; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy
Interventions: HYD, Moxifloxacin, Placebo for HYD, Placebo for moxifloxacin; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Post Operative Pain
Interventions: Norco 7.5mg/325, MNK155; Drug
Lead sponsor: Neil Singla; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Opiate Addiction
Interventions: Suboxone, CRA, Therapy, CM; Drug · Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

Opiates and Benzodiazepines on Driving

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery

Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

Acute Pain Study Following Bunionectomy

Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment

Postoperative Pain Management in Rhinoplasty

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

TAP Block With Plain Bupivacaine Versus Wound Infiltration With Exparel for Postoperative Pain Management

Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain

Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)